vimarsana.com

Latest Breaking News On - Biofactura inc - Page 1 : vimarsana.com

BioFactura, CuraTeQ sign exclusive license for Crohn s disease drug

BioFactura, CuraTeQ sign exclusive license for Crohn s disease drug
thedailyrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedailyrecord.com Daily Mail and Mail on Sunday newspapers.

New zealandUnited kingdomAndhra pradeshStelara ustekinumabBiofactura incEuropean unionAurobindo pharmaCurateq biologics privateFrederick based biofacturaCurateq biologics private limitedAurobindo pharma limitedEmerging markets

Sensex, Nifty Live updates: Indices gain 0 3% in early trade; Reliance Industries top gainer, HCL Tech under pressure

Sensex, Nifty Live updates: Indices gain 0 3% in early trade; Reliance Industries top gainer, HCL Tech under pressure
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

United statesIndia generalWest bengalUnited arab emiratesSeptember brentAurobindo pharmaUsha martinBharti airtelSociete genealeGautam adaniTata motorsSuzlon energyMotilal oswal financial servicesVedanta groupVedanta foxconn semiconductors privatePoonawalla housing finance

BioFactura and CuraTeQ Sign Exclusive License for BFI-751—A Biosimilar to Stelara

Frederick, Maryland (PRWEB) July 10, 2023 BioFactura, Inc. today announced that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo

Andhra pradeshUnited kingdomCurateq biologicsNithyananda reddyDarryl sampeyStelara ustekinumabJeffreyn hausfeldAurobindo pharmaSatakarni makkapatiBiofactura incAurobindo pharma ltdCurateq biologics privateChief medical officerCurateq biologics private limitedAurobindo pharma limitedEmerging markets

Trade setup for Monday: Top 15 things to know before the opening bell

The earnings season gets underway this week and market participants will track Q1 numbers along with management commentaries as domestic demand remains a concern. Valuations are rich, a disappointment in earnings can derail the market rally

United statesBharti airtelNagaraj shettiKunal shahStelara ustekinumabLarsen toubroAurobindo pharmaTechnical research analystZydus life sciencesHousing development finance corporationAarti industriesTitan companyBiofactura incReliance industriesIndian oil corporationBank nifty

Aurobindo Pharma Subsidiary CuraTeQ Biologics Entered Into An Agreement With US-based BioFactura

Ustekinumab is a recombinant monoclonal antibody which is used for treating Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

United kingdomUnited statesStelara ustekinumabBiofactura incAurobindo pharmaCurateq biologicsEmerging markets

vimarsana © 2020. All Rights Reserved.